Vanguard Group Inc. Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,964,394 shares of the medical research company’s stock after purchasing an additional 600,994 shares during the period. Vanguard Group Inc. owned about 8.79% of Edwards Lifesciences worth $5,061,277,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Intech Investment Management LLC grew its position in shares of Edwards Lifesciences by 1,269.8% during the first quarter. Intech Investment Management LLC now owns 225,333 shares of the medical research company’s stock worth $21,533,000 after buying an additional 208,883 shares in the last quarter. M&G Plc acquired a new position in shares of Edwards Lifesciences during the first quarter worth about $853,000. CCLA Investment Management grew its position in shares of Edwards Lifesciences by 100,739.7% during the first quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock worth $134,092,000 after buying an additional 1,405,319 shares in the last quarter. Trillium Asset Management LLC grew its position in shares of Edwards Lifesciences by 0.5% during the first quarter. Trillium Asset Management LLC now owns 110,761 shares of the medical research company’s stock worth $10,584,000 after buying an additional 519 shares in the last quarter. Finally, Maple Capital Management Inc. grew its position in shares of Edwards Lifesciences by 13.6% during the first quarter. Maple Capital Management Inc. now owns 3,575 shares of the medical research company’s stock worth $342,000 after buying an additional 428 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,250 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total transaction of $622,050.00. Following the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,636,549.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,250 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total value of $622,050.00. Following the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,099 shares of company stock worth $7,003,553. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.8 %

Shares of Edwards Lifesciences stock traded up $0.69 during trading hours on Friday, reaching $86.50. The stock had a trading volume of 2,433,949 shares, compared to its average volume of 3,261,662. The firm has a 50 day simple moving average of $89.11 and a two-hundred day simple moving average of $86.82. The firm has a market capitalization of $52.12 billion, a price-to-earnings ratio of 37.28, a P/E/G ratio of 3.17 and a beta of 1.11. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on EW shares. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Evercore ISI upped their price target on Edwards Lifesciences from $89.00 to $91.00 and gave the company an “in-line” rating in a report on Tuesday, July 2nd. Barclays upped their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. Stifel Nicolaus upped their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday, April 26th. Finally, Truist Financial upped their price target on Edwards Lifesciences from $105.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $96.13.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.